Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 1
1952 7
1953 8
1954 10
1955 13
1956 7
1957 5
1958 3
1959 1
1961 1
1962 1
1965 12
1966 18
1967 25
1968 63
1969 54
1970 80
1971 87
1972 93
1973 92
1974 104
1975 96
1976 88
1977 72
1978 100
1979 105
1980 124
1981 114
1982 119
1983 97
1984 135
1985 135
1986 122
1987 142
1988 153
1989 165
1990 203
1991 163
1992 178
1993 177
1994 199
1995 232
1996 236
1997 230
1998 253
1999 264
2000 245
2001 295
2002 289
2003 400
2004 413
2005 448
2006 490
2007 514
2008 546
2009 571
2010 639
2011 661
2012 763
2013 762
2014 749
2015 702
2016 733
2017 710
2018 781
2019 825
2020 772
2021 713
2022 645
2023 526
2024 166

Text availability

Article attribute

Article type

Publication date

Search Results

17,181 results

Results by year

Filters applied: . Clear all
Page 1
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.
Becker JC, Stang A, Schrama D, Ugurel S. Becker JC, et al. Am J Clin Dermatol. 2024 Apr 22. doi: 10.1007/s40257-024-00858-z. Online ahead of print. Am J Clin Dermatol. 2024. PMID: 38649621 Review.
Merkel cell carcinoma (MCC) is a rare skin cancer characterized by neuroendocrine differentiation. ...However, owing to the rarity of MCC and the lack of epidemiologic registries with detailed clinical data, there is some uncertainty regarding the spontaneous …
Merkel cell carcinoma (MCC) is a rare skin cancer characterized by neuroendocrine differentiation. ...However, owing to the ra …
Comparison of skin cancer risk between renal transplant recipients and patients with glomerular diseases in rural Queensland.
Thet Z, Lam AK, Ng SK, Aung SY, Han T, Ranganathan D, Newsham S, Borg J, Pepito C, Khoo TK. Thet Z, et al. Aust J Rural Health. 2024 Apr;32(2):249-262. doi: 10.1111/ajr.13081. Epub 2024 Jan 19. Aust J Rural Health. 2024. PMID: 38646861
INTROUDCTION: There is increased risk of skin cancer in patients with gloermular disease or those with renal transplant. ...FINDINGS: KTRs with non-melanoma skin carcinoma (NMSC) increased significantly after treatment with immunosuppressants (pre-transplanta …
INTROUDCTION: There is increased risk of skin cancer in patients with gloermular disease or those with renal transplant. ...FINDINGS: …
Urethral carcinoma after skin substitution urethral reconstruction.
Wu Z, Chen M, Mori R. Wu Z, et al. Can J Urol. 2024 Apr;31(2):11858-11860. Can J Urol. 2024. PMID: 38642465
Skin substitution urethroplasty is subjected to higher rates of recurrence, which lends to the potential for carcinogenesis. We present a case of a 59-year-old male who underwent multi-stage skin substitution urethroplasty who developed urethral carcinoma 20
Skin substitution urethroplasty is subjected to higher rates of recurrence, which lends to the potential for carcinogenesis. We prese
Fragile hands: targeting nonmelanoma skin cancer on older hands using 595 nm pulsed dye laser.
Herron ED, Snyder AM, Hull CM, LoBello S, Herron MD. Herron ED, et al. Lasers Med Sci. 2024 Apr 17;39(1):101. doi: 10.1007/s10103-024-04047-6. Lasers Med Sci. 2024. PMID: 38630146
PURPOSE: The mainstay of treatment for nonmelanoma skin cancer (NMSC) on thin skin remains surgical, but procedures on older hands may be complicated by skin fragility and dermal atrophy. ...METHODS: A retrospective chart review identified 147 cases of NMSC l …
PURPOSE: The mainstay of treatment for nonmelanoma skin cancer (NMSC) on thin skin remains surgical, but procedures on older h …
Skin Cancer Risk of Narrow-Band UV-B (TL-01) Phototherapy: A Multi-Center Registry Study with 4,815 Patients.
Åkerla P, Pukkala E, Helminen M, Korhonen N, Karppinen T. Åkerla P, et al. Acta Derm Venereol. 2024 Apr 17;104:adv39927. doi: 10.2340/actadv.v104.39927. Acta Derm Venereol. 2024. PMID: 38629891 Free article.
Standardized incidence ratios were calculated for basal cell carcinoma, cutaneous melanoma, and squamous cell carcinoma. The standardized incidence ratio for basal cell carcinoma was 2.5 (95% confidence interval 1.8-3.5), for cutaneous melanoma 4.0 (95% confi …
Standardized incidence ratios were calculated for basal cell carcinoma, cutaneous melanoma, and squamous cell carcinoma. The s …
Impact of immune-related adverse events on survival outcomes in extensive-stage small cell lung cancer patients treated with immune checkpoint inhibitors.
Nishimura T, Fujimoto H, Fujiwara T, Ito K, Fujiwara A, Yuda H, Itani H, Naito M, Kodama S, Furuhashi K, Yagi A, Saiki H, Yasuma T, Okano T, Tomaru A, Tanigawa M, Yoshida M, Hataji O, Ibata H, D'Alessandro-Gabazza CN, Gabazza EC, Kobayashi T. Nishimura T, et al. Cancer Med. 2024 Apr;13(8):e7188. doi: 10.1002/cam4.7188. Cancer Med. 2024. PMID: 38629295 Free PMC article.
Seventeen patients had grade 1-2 immune-related adverse events, and nine (including overlapping cases) had grade 3. The most frequent immune-related adverse event was a skin rash. The median survival time was 22 months in patients with immune-related adverse events and 9.3 …
Seventeen patients had grade 1-2 immune-related adverse events, and nine (including overlapping cases) had grade 3. The most frequent immune …
Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
Hong S, Lee JH, Heo JY, Suh KJ, Kim SH, Kim YJ, Kim JH. Hong S, et al. J Cancer Res Clin Oncol. 2024 Apr 10;150(4):186. doi: 10.1007/s00432-024-05728-z. J Cancer Res Clin Oncol. 2024. PMID: 38600328 Free PMC article.
This study aimed to investigate the impact of concurrent medications on the clinical outcomes of patients with cancer receiving ICI therapy in South Korea. ...CONCLUSION: A high number of concurrent medications was associated with poor clinical outcomes....
This study aimed to investigate the impact of concurrent medications on the clinical outcomes of patients with cancer receiving ICI t …
Case report: Envafolimab causes local skin necrosis.
Liu JJ, Xu XY, Han H, Wang T, Zhang W, Cui J, Semenov M. Liu JJ, et al. Front Immunol. 2024 Mar 22;15:1336311. doi: 10.3389/fimmu.2024.1336311. eCollection 2024. Front Immunol. 2024. PMID: 38585260 Free PMC article.
Envafolimab is used to treat adult patients with previously treated microsatellite instability-high (MSI-H) or deficient mismatch repair (dMMR) advanced solid tumors, including patients with advanced colorectal cancer disease progression who were previously administered fluoroura …
Envafolimab is used to treat adult patients with previously treated microsatellite instability-high (MSI-H) or deficient mismatch repair (dM …
Accuracy of an artificial intelligence as a medical device as part of a UK-based skin cancer teledermatology service.
Marsden H, Kemos P, Venzi M, Noy M, Maheswaran S, Francis N, Hyde C, Mullarkey D, Kalsi D, Thomas L. Marsden H, et al. Front Med (Lausanne). 2024 Mar 22;11:1302363. doi: 10.3389/fmed.2024.1302363. eCollection 2024. Front Med (Lausanne). 2024. PMID: 38585154 Free PMC article.
Secondary endpoints included the sensitivity, specificity, positive and negative predictive values, and number needed to biopsy to identify one case of melanoma or squamous cell carcinoma (SCC) by both the AIaMD and SoC. METHODS: This prospective, single-centre, single-arm …
Secondary endpoints included the sensitivity, specificity, positive and negative predictive values, and number needed to biopsy to identify …
FDG PET/CT in the Diagnosis and After Sunitinib Follow-up of Synchronous Base of Tongue and Thyroid Metastases From Renal Cell Carcinoma.
Kumar SA, Mittal BR, Kumar S, Singh H, Kumar R, Bal A. Kumar SA, et al. Clin Nucl Med. 2024 May 1;49(5):e208-e210. doi: 10.1097/RLU.0000000000005152. Clin Nucl Med. 2024. PMID: 38574256
Renal cell carcinoma (RCC) is a leading cause of mortality among genitourinary malignancies with limited therapeutic options. ...Usually, metastases are regional lymph nodes, lungs, bone, liver, adrenal glands, contralateral kidney, and brain. Metastases to the rare sites …
Renal cell carcinoma (RCC) is a leading cause of mortality among genitourinary malignancies with limited therapeutic options. ...Usua …
17,181 results
You have reached the last available page of results. Please see the User Guide for more information.